Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Phase 3

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: Thymoglobulin
Drug: Daclizumab
Other: Plasmapheresis
Drug: Mycophenolate mofetil
Drug: Tacrolimus
Drug: Dexamethasone
Drug: Prednisone
Drug: Cytogam

First Posted Date: 2006-01-12

Last Posted Date: 2018-01-18

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 56

Registration Number: NCT00275509

Locations: 🇺🇸
The Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: carboplatin
Drug: prednisone
Drug: etoposide
Drug: vincristine
Drug: ifosfamide

First Posted Date: 2006-01-11

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 100

Registration Number: NCT00274924

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States

and more 99 locations

A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids

Conditions: Kidney Diseases

Interventions: Drug: prednisone

First Posted Date: 2006-01-09

Last Posted Date: 2008-05-12

Lead Sponsor: Florida Hospital Transplant Center

Target Recruit Count: 60

Registration Number: NCT00273559

Locations: 🇺🇸
Florida Hospital Transplant Center, Orlando, Florida, United States

Prednisone Treatment for Vestibular Neuronitis

Phase 2

Completed

Conditions: Vestibular Diseases
Vestibular Neuronitis

Interventions: Drug: Prednisone

First Posted Date: 2006-01-04

Last Posted Date: 2007-11-06

Lead Sponsor: Carmel Medical Center

Target Recruit Count: 17

Registration Number: NCT00271791

Locations: 🇮🇱
Department of Otolaryngology Head and Neck Surgery, Carmel Medical Center, Haifa, Israel
🇮🇱
Otoneurolgy Unit, Lin Medical Center, Clalit Health Services, Haifa, Israel
🇮🇱
Unit of Otolaryngology Head and Neck Surgery, Hillel Yaffe Medical Center, Hadera, Israel

and more 1 locations

Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: PI-88
Drug: docetaxel
Drug: prednisone

First Posted Date: 2005-12-22

Last Posted Date: 2011-06-15

Lead Sponsor: Progen Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT00268593

Locations: 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺
Sydney Haematology and Oncology Clinics, Hornsby, New South Wales, Australia
🇦🇺
Lismore Base Hospital, Lismore, New South Wales, Australia

and more 5 locations

Aerosol Cyclosporine for Prevention of Lung Rejection

Phase 2

Completed

Conditions: Lung Diseases

First Posted Date: 2005-12-22

Last Posted Date: 2016-05-13

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00268515

HD12 for Advanced Stages

Phase 3

Completed

Conditions: Hodgkin´s Lymphoma

First Posted Date: 2005-12-13

Last Posted Date: 2012-06-25

Lead Sponsor: University of Cologne

Registration Number: NCT00265031

HD11 for Intermediate Stages

Phase 3

Completed

Conditions: Hodgkin´s Lymphoma

Interventions: Drug: Adriamycin
Drug: Bleomycin
Drug: Vinblastine
Drug: Etoposide
Drug: DTIC
Drug: Procarbazine
Radiation: radiation therapy
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2005-12-13

Last Posted Date: 2011-08-04

Lead Sponsor: University of Cologne

Target Recruit Count: 1395

Registration Number: NCT00264953

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: custirsen sodium
Drug: docetaxel
Drug: prednisone

First Posted Date: 2005-11-24

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 82

Registration Number: NCT00258388

Locations: 🇨🇦
London Regional Cancer Program, London, Canada
🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, Canada
🇺🇸
University of Washington, Seattle, Washington, United States

and more 10 locations

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: prednisone

First Posted Date: 2005-11-21

Last Posted Date: 2013-06-26

Lead Sponsor: Tampere University

Target Recruit Count: 360

Registration Number: NCT00255606

Locations: 🇫🇮
Keski-Pohjanmaa Central Hospital, Kokkola, Finland
🇸🇪
Karolinska University Hospital - Solna, Stockholm, Sweden
🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland

and more 15 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy